Results of a phase II trial of single-agent amrubicin (AMR) in patients with extensive disease small cell lung cancer (ED-SCLC) refractory to first-line platinum-based chemotherapy: An update

D. S. Ettinger, R. Jotte, P. Lorigan, V. Gupta, L. Garbo, P. Conkling, D. Spigel, R. McNally, M. Renschler, J. Oliver

    Research output: Contribution to journalMeeting Abstractpeer-review

    Original languageUndefined
    Article number8103
    JournalJournal of Clinical Oncology
    Issue number15 Supplement
    Publication statusPublished - 20 May 2009

    Cite this